Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of eplontersen in Chinese patients with transthyretin amyloid cardiomyopathy
CTR20233114Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of eplontersen in amyloidotic transthyretin cardiomyopathy (ATTR-CM), familial amyloid cardiomyopathy (FAC), wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM), sponsored by AstraZeneca. Started Jan 2024; status: active.
02
Drugs
eplontersen
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)familial amyloid cardiomyopathy (FAC)wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM)
Beyond the preview
Go deeper on CTR20233114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233114.